How does aCGH work?
array Comparative Genomic Hybridization (aCGH) is a molecular cytogenetic method that scans the genome for any alterations in a rapid manner.
Unlock personalized cancer care. Book a Test Now
array Comparative Genomic Hybridization (aCGH) test, a microarray-based technique and the most precise tool available today detects the unbalanced structural and numerical chromosomal abnormalities that exist in a cancer patient. The test is beneficial when a patient may be diagnosed with a cancer of unknown origin. In such cases, aCGH helps point the doctor in the right direction by identifying chromosomal abnormalities associated with specific types of cancer.
array Comparative Genomic Hybridization (aCGH) is a molecular cytogenetic method that scans the genome for any alterations in a rapid manner.
aCGH is a powerful technique that compares DNA content from two genomes: a test (or patient) genome and a reference (or control) genome. Chromosomes go through many aberrations like an addition, deletion or structural of a segment or more than one segment in a gene. aCGH enables the detection of these chromosomal abnormalities within genes.
This comprehensive analysis aids in understanding the underlying genetic factors contributing to the disease. By identifying chromosomal abnormalities, the test assists in determining the potential location of the primary tumor, providing critical information for diagnosis and treatment planning.
Reserve your 30-minute free consultation
With the detection of abnormalities in the chromosomes, aCGH enables us to identify the type of cancer the patient has been affected with.
It enables precise and fast detection of abnormalities in the entire genome sequence with very high resolution.
It provides clinicians with personalized chromosomal analysis for their unique cancer journey.
Oncotrail has undergone rigorous evaluation to ensure high sensitivity and specificity, making it an invaluable tool for diagnostic purposes.
Through high-precision techniques, the test is used to monitor the effectiveness of a particular cancer treatment. This would objectively provide information on how well the treatment is going.
The non-invasive tracking of the cancer status would notify a treating physician whether to adjust current management or stay the course. This would be important to know in almost real-time rather than to find out much later that a treatment doesn't apply to a particular person.
Whole peripheral blood sample
10-15 ml of whole peripheral blood
2-3 weeks in the lab
30 days after sample collection
Applicable for all cancer types
To whom it is relevant: The test is recommended for patients with a confirmed cancer diagnosis.
A patient-centric revolution in cancer testing and monitoring. We are devoted to providing personalized tests designed with each patient’s unique genetic profile in mind.
©2024 All Rights Reserved. Designed by Bee High Media.